2022-12-19 08:22:56 ASMB Assembly Biosciences
12/19/22 12/1908:22 12/19/2208:22 | Assembly announces interim results from studies on ABI-H3733, ABI-4334Assembly Biosciences announced promising interim efficacy, safety and pharmacokinetic results from two ongoing clinical studies of its investigational next-generation HBV core inhibitors, a Phase 1b clinical study of ABI-H3733 and a Phase 1a clinical study of ABI-4334. Phase 1b Study for 3733 - Study ABI-H3733-102: The ongoing Phase 1b clinical trial is a randomized, multi-center, double-blind and placebo-controlled study evaluating the safety, PK and antiviral activity of 3733. The dose selected for the first cohort was 50 mg. 50 mg Cohort Efficacy: As of the data cutoff date of December 18, 2022, dosing in the 3733 Phase 1b trial has been completed for all 10 patients in the first cohort of 50 mg. Nine of 10 patients enrolled were HBeAg negative, so efficacy data are provided for these patients. Interim efficacy results from this cohort at the data cutoff date include HBV DNA, HBV RNA and antigen measurements for all patients for the full 28-day dosing period. In the 50 mg cohort, six of eight patients receiving 3733 achieved HBV DNA less than the lower limit of quantification within 21 days, with a mean decline in HBV DNA over the treatment period of approximately 3.1 logs. Data on HBV RNA declines were limited due to low baseline levels in predominantly e-antigen negative patients. 25 mg Cohort Efficacy: The second cohort, evaluating a dose of 25 mg, is fully enrolled. Nine of 10 patients enrolled were HBeAg negative, so efficacy data are provided for these patients. In the five patients that have so far completed 28 days of treatment, the mean reduction in HBV DNA was approximately 1.9 logs. 50 and 25 mg Cohorts: Safety data reported here reflect data received for both cohorts through the data cutoff date. In these initial cohorts, all treatment-emergent adverse events and laboratory abnormalities reported were Grade 1 or Grade 2. Further, no AEs led to treatment discontinuation. The observed PK for the new tablet formulation of 3733 was consistent with predictions from preclinical studies, providing exposure equivalent to the liquid formulation evaluated in the Phase 1a study for 3733. As expected given the 28-day dosing period, limited changes in viral antigens were observed in both the 50 mg and 25 mg cohorts. Phase 1a Study for 4334 - Study ABI-4334-101: The Phase 1a clinical trial is a randomized, blinded and placebo-controlled study evaluating the safety, tolerability and PK of 4334 following single ascending dose and multiple ascending dose administration in healthy subjects. Dosing has completed for all eight subjects in the initial 30 mg single dose cohort. In this cohort, 4334 had a mean half-life of 24 hours, supporting once-a-day dosing. In this initial cohort, treatment-emergent AEs and laboratory abnormalities were mild to moderate and all were considered not related to study treatment. A dose of 100 mg has been selected for the second single-dose cohort. Dosing for the second cohort is complete and initial data from this cohort are anticipated in the first quarter of 2023. |
---|
Downgrade
|
China Tourism Group Duty downgraded to Buy from Conviction Buy at Goldman Sachs »
16:31 05/28/23 05/2816:31 05/28/2316:31
CTGDF
China Tourism Group Duty
Goldman Sachs analyst… Story temporarily locked. |
On The Fly
|
Short Report: Bears reload on Mobileye after sharp gains in stock price »
12:36 05/27/23 05/2712:36 05/27/2312:36
MBLY
Mobileye
Beyond Meat
Enliven
Plug Power
Chewy
EVgo
Welcome to this week’s… ShowHide Related Items >><<
|
Hot Stocks
|
Attorneys announce over $500M pact with Eli Lilly to settle class-action suit »
18:17 05/26/23 05/2618:17 05/26/2318:17
LLY
Eli Lilly
Attorneys at Hagens… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
StoneCo names Mateus Scherer Schwening CFO »
17:39 05/26/23 05/2617:39 05/26/2317:39
STNE
StoneCo
StoneCo announced key… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Iovance Biotherapeutics announces FDA acceptance of BLA of Lifileucel »
17:33 05/26/23 05/2617:33 05/26/2317:33
IOVA
Iovance Biotherapeutics
Iovance Biotherapeutics… Story temporarily locked. ShowHide Related Items >><<
|
Syndicate
|
Athersys files to sell 5.685M shares of common stock for holders »
17:32 05/26/23 05/2617:32 05/26/2317:32
ATHX
Athersys
The company will not… Story temporarily locked. ShowHide Related Items >><<
|
Periodicals
|
Google ordered to pay Sonos $32.5M in patent infringement case, Verge says »
17:31 05/26/23 05/2617:31 05/26/2317:31
GOOG
Alphabet
Alphabet
Sonos
A jury verdict issued in… Story temporarily locked. ShowHide Related Items >><<
|
Syndicate
|
Salarius Pharmaceuticals files ot sell 11.16M shares of common stock for holders
17:05 05/26/23 05/2617:05 05/26/2317:05
SLRX
Salarius Pharmaceuticals
ShowHide Related Items >><<
|
General news
|
Treasury reported a $38.8 B cash balance as of May 25 »
17:05 05/26/23 05/2617:05 05/26/2317:05
$ECON
Economic Data
Treasury reported a $38.8… Story temporarily locked. ShowHide Related Items >><<
|
Syndicate
|
Bicycle Therapeutics files automatic mixed securities shelf
16:58 05/26/23 05/2616:58 05/26/2316:58
BCYC
Bicycle Therapeutics
ShowHide Related Items >><<
|
Hot Stocks
|
ETAO International receives Nasdaq deficiency letter »
16:51 05/26/23 05/2616:51 05/26/2316:51
ETAO
ETAO International
On May 18, 2023, Etao… Story temporarily locked. |
Hot Stocks
|
Cboe Global Markets director Ratterman sells 15,000 common shares »
16:49 05/26/23 05/2616:49 05/26/2316:49
CBOE
Cboe Global Markets
In a regulatory filing,… Story temporarily locked. ShowHide Related Items >><<
|
Upgrade
|
Universal Health upgraded to Outperform from Market Perform at SVB Securities »
16:41 05/26/23 05/2616:41 05/26/2316:41
UHS
Universal Health
SVB Securities analyst… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Noble Corp. CEO Eifler sells 50,000 ordinary shares »
16:40 05/26/23 05/2616:40 05/26/2316:40
NE
Noble Corp.
In a regulatory filing,… Story temporarily locked. ShowHide Related Items >><<
|
Syndicate
|
Innovative Eyewear files to sell 300K shares of common stock for holders »
16:38 05/26/23 05/2616:38 05/26/2316:38
LUCY
Innovative Eyewear
The company will not… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Smart Powerr receives noncompliance notification from Nasdaq »
16:31 05/26/23 05/2616:31 05/26/2316:31
CREG
Smart Powerr
Smart Powerr announced… Story temporarily locked. ShowHide Related Items >><<
|
Options
| Preliminary option volume… Story temporarily locked. |
Syndicate
|
Sempra Energy files automatic mixed securities shelf
16:25 05/26/23 05/2616:25 05/26/2316:25
SRE
Sempra Energy
ShowHide Related Items >><<
|
On The Fly
|
What You Missed On Wall Street On Friday »
16:24 05/26/23 05/2616:24 05/26/2316:24
WBA
Walgreens Boots Alliance
JPMorgan
First Republic Bank
Teva
New Relic
Deutsche Bank
Ford
Costco
Tesla
Workday
Gap
ConocoPhillips
TotalEnergies
Guardant Health
MongoDB
Paramount
Paramount
eFfector Therapeutics
Terran Orbital
Coherent
PDD Holdings
Geron
Tilray
DLocal
Marvell
Ulta Beauty
Autodesk
Hibbett
Big Lots
Get caught up quickly on… ShowHide Related Items >><<
|
Hot Stocks
|
Coinbase exec Brock sells 14,207 class A shares »
16:22 05/26/23 05/2616:22 05/26/2316:22
COIN
Coinbase
In a regulatory filing,… Story temporarily locked. ShowHide Related Items >><<
|
General news
| Treasury Market Summary:… Story temporarily locked. ShowHide Related Items >><<
|
Options
|
Closing CBOE SPX and VIX Index summary for May 26th »
16:20 05/26/23 05/2616:20 05/26/2316:20
VIX
Volatility Index S&P 500 Options
The CBOE Volatility Index… Story temporarily locked. ShowHide Related Items >><<
|
Technical Analysis
|
NASDAQ market internals summary »
16:17 05/26/23 05/2616:17 05/26/2316:17
$NSD
NASDAQ Market Internals
Volume was above average… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
TransDigm names Mike Lisman, Joel Reiss co-COOs, Wynne named CFO »
16:16 05/26/23 05/2616:16 05/26/2316:16
TDG
TransDigm
TransDigm Group… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
TransDigm names Mike Lisman, Joel Reiss co-COOs, Wynne named CFO »
16:16 05/26/23 05/2616:16 05/26/2316:16
TDG
TransDigm
Wynne has assumed the… Story temporarily locked. |